Exploring Safety in Gender-Affirming Hormonal Treatments: An Observational Study on Adverse Drug Events Using the Food and Drug Administration Adverse Event Reporting System Database
CONCLUSIONS AND RELEVANCE: The FAERS data reveal significant ADRs in transgender individuals using hormone therapy, sometimes unintended for their recipient gender. Population-level studies are crucial to enhance transgender health care. Spontaneous surveillance databases like FAERS illuminate off-label ADRs, urging health care providers to approach hormone therapies with informed caution.PMID:38347713 | DOI:10.1177/10600280241231612 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 13, 2024 Category: Drugs & Pharmacology Authors: Ainhoa Gomez-Lumbreras Lorenzo Villa-Zapata Source Type: research
Real-World Incidence and Severity of Hypertension Caused by Abiraterone Acetate in Patients With Metastatic Prostate Cancer
CONCLUSION AND RELEVANCE: This single-center, retrospective cohort study found that real-world metastatic prostate cancer patients who received AA had substantially higher incidence and severity of hypertension compared with clinical trials regardless of prednisone dose. In patients with mCRPC and mCSPC, the role of prednisone dose in hypertension incidence and severity warrants further investigation. Overall, results indicate the need for closely monitoring hypertension and optimization of anti-hypertensive therapy by multidisciplinary teams in metastatic prostate cancer patients receiving AA.PMID:38344981 | DOI:10.1177/1...
Source: The Annals of Pharmacotherapy - February 12, 2024 Category: Drugs & Pharmacology Authors: Brian Lam Jo E Rodgers Benyam Muluneh Darrian Proco Young E Whang Katherine P Morgan Source Type: research
Mirikizumab: A New Therapeutic Option for the Treatment of Ulcerative Colitis
CONCLUSION: Mirikizumab provides a novel mechanism of action for the treatment of moderate to severe UC and is another welcomed treatment advance in the treatment arsenal, providing a more selective mechanism of action while maintaining a comparable safety profile.PMID:38344998 | DOI:10.1177/10600280241229742 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 12, 2024 Category: Drugs & Pharmacology Authors: David Choi Hilary Sheridan Shubha Bhat Source Type: research
The Impact of Glycemic Control on Sodium-Glucose Co-Transporter 2 Inhibitor-Associated Genitourinary Infections
CONCLUSIONS AND RELEVANCE: Type 2 diabetes patients initiated on SGLT2is may experience an increased risk of GU infection, especially in those patients with an A1C of 9% or greater. Further research is necessary to validate and expand upon these findings.PMID:38321772 | DOI:10.1177/10600280241227973 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 7, 2024 Category: Drugs & Pharmacology Authors: Anthony Gerber Victoria Rupp Natalia Ryabenkova Nataliya Mikhelzon Source Type: research
Clinical Response to Third-Line Angiotensin-II vs Epinephrine in Septic Shock: A Propensity-Matched Cohort Study
CONCLUSIONS AND RELEVANCE: Administration of AT-II as a third-line vasopressor agent in septic shock patients was not associated with significantly improved clinical response at hour 24 compared with epinephrine. Although underpowered to detect meaningful differences, the clinical observations of this study warrant consideration and further investigation of AT-II as a third-line vasopressor in septic shock.PMID:38303571 | DOI:10.1177/10600280231226132 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - February 2, 2024 Category: Drugs & Pharmacology Authors: Caitlyn R Blankenship Kevin D Betthauser Laura N Hencken Julie A Maamari Jenna Goetz Bria D Giacomino Gabrielle A Gibson Source Type: research
Evaluation of a Pharmacist-Led Implementation of Standardized Medication Administration Times for Inpatients Receiving Hemodialysis
CONCLUSION AND RELEVANCE: A pharmacist-led intervention for standard medication administration times in patients requiring hemodialysis increased the number of prescribed medication doses given and given on time. The intervention also led to more antimicrobials administered at appropriate times relative to dialysis sessions.PMID:38293819 | DOI:10.1177/10600280231220079 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - January 31, 2024 Category: Drugs & Pharmacology Authors: Abbie L Blunier Megan R Cheatham Karishma S Deodhar Christopher A Geik Todd A Walroth Jessica A Whitten Christie M Davis Source Type: research
Monoclonal Antibody Infusions for Outpatient Management of Mild-Moderate COVID-19
CONCLUSION AND RELEVANCE: Overall, the mAbs appeared safe and effective. Sicker, higher-risk mAb-treated veterans faired similarly to less-sick, high-risk veterans not treated. Those who were vaccinated seemed to benefit the most from mAb therapy. Future prospective studies with more matched groups are needed to assess full benefits and risks of mAbs shown to neutralize the predominant variants.PMID:38288555 | DOI:10.1177/10600280231222465 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - January 30, 2024 Category: Drugs & Pharmacology Authors: Hannah B Knox Lisa A Dykes Lancer A Scott Bradley C Presley Lara C Lambert Source Type: research
Epidemiology of Vancomycin in Combination With Piperacillin/Tazobactam-Associated Acute Kidney Injury in Children: A Systematic Review and Meta-analysis
CONCLUSIONS: The incidence of VPT-associated AKI in children is high, especially in critically ill children. Medication regimens should be personalized based on the presence of individual risk factors. Moreover, renal function was regularly assessed throughout treatment with VPT.PMID:38279799 | DOI:10.1177/10600280231220379 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - January 27, 2024 Category: Drugs & Pharmacology Authors: Miao Zhang Liang Huang Yu Zhu Linan Zeng Zhi-Jun Jia Guo Cheng Hailong Li Lingli Zhang Source Type: research
Documentation of the Patient Characteristics Morbid Obesity and Bariatric Surgery in the Hospital Information System and the Influence on the Number of Medication-Related Problems
CONCLUSION AND RELEVANCE: The proportion of patients with documentation of the patient characteristics bariatric surgery and/or morbid obesity in the HIS is low, which appears to be associated with more MRPs. To improve medication safety, it is important to document these patient characteristics.PMID:38268179 | DOI:10.1177/10600280231226243 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - January 25, 2024 Category: Drugs & Pharmacology Authors: Jurjen S Kingma Iris A M Brenkman Marcel P H van den Broek Patricia M L A van den Bemt Karin Janssen Catherijne A J Knibbe Desir ée M T Burgers Source Type: research
Etrasimod: A Sphingosine-1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis
CONCLUSION: Etrasimod is another possibility in the armamentarium of UC treatment, providing patients with more oral medication options. Prior to treatment initiation, several assessments relating to safety, drug interactions, and pharmacogenomics factors are advised.PMID:38258760 | DOI:10.1177/10600280231225770 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - January 23, 2024 Category: Drugs & Pharmacology Authors: David Choi Michelle Becker Marina Ivanov Shubha Bhat Source Type: research
Impact of a Divided Phenobarbital Load and Taper Compared With Lorazepam Symptom Triggered Therapy in Hospitalized Patients
CONCLUSION AND RELEVANCE: This study is novel because of the broad application of a phenobarbital order set across multiple levels of care and patient admission diagnoses. A risk targeted split load intravenous phenobarbital order set can safely be administered to patients with fewer escalations of care, seizures, delirium tremens, and respiratory care escalation.PMID:38258797 | DOI:10.1177/10600280231222294 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - January 23, 2024 Category: Drugs & Pharmacology Authors: Alyson M Esteves Matthew C Buchfellner Brooke M Holmes Joseph A Berndsen Matthew A Roginski Source Type: research
Phenobarbital Versus Benzodiazepines for the Treatment of Severe Alcohol Withdrawal
CONCLUSION AND RELEVANCE: Scheduled phenobarbital was associated with decreased hospital LOS compared to benzodiazepines for SAWS. This was the first study to compare outcomes of fixed-dose, nonoverlapping phenobarbital to benzodiazepines in patients with clearly defined SAWS and details a readily implementable protocol.PMID:38247044 | DOI:10.1177/10600280231221241 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - January 22, 2024 Category: Drugs & Pharmacology Authors: Katherine M Kessel Logan M Olson Derek A Kruse Elizabeth R Lyden Kelsey E Whiston Mindy M Blodgett Alena A Balasanova Source Type: research
Reply: Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice
Ann Pharmacother. 2024 Jan 21:10600280231224021. doi: 10.1177/10600280231224021. Online ahead of print.NO ABSTRACTPMID:38247049 | DOI:10.1177/10600280231224021 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - January 22, 2024 Category: Drugs & Pharmacology Authors: Courtney L Bradley Sara M McMillin Andrew Y Hwang Christina H Sherrill Source Type: research
Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice
Ann Pharmacother. 2024 Jan 21:10600280231224039. doi: 10.1177/10600280231224039. Online ahead of print.NO ABSTRACTPMID:38247052 | DOI:10.1177/10600280231224039 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - January 22, 2024 Category: Drugs & Pharmacology Authors: Sarita Jacob George I Varughese Source Type: research
Pirtobrutinib: A New and Distinctive Treatment Option for B-Cell Malignancies
CONCLUSION: The characteristics of pirtobrutinib render it useful in the treatment of B-cell malignancies no longer responding to a previous BTK inhibitor, and results from ongoing clinical trials may support future expanded use.PMID:38235739 | DOI:10.1177/10600280231223737 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - January 18, 2024 Category: Drugs & Pharmacology Authors: Madeline D Schultze David J Reeves Source Type: research
